99 related articles for article (PubMed ID: 9388049)
1. Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart.
Park JL; Tanhehco EJ; Kilgore KS; Gralinski MR; Lucchesi BR
J Cardiovasc Pharmacol; 1997 Nov; 30(5):658-66. PubMed ID: 9388049
[TBL] [Abstract][Full Text] [Related]
2. LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart.
Gralinski MR; Park JL; Ozeck MA; Wiater BC; Lucchesi BR
J Pharmacol Exp Ther; 1997 Aug; 282(2):554-60. PubMed ID: 9262315
[TBL] [Abstract][Full Text] [Related]
3. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart.
Kilgore KS; Naylor KB; Tanhehco EJ; Park JL; Booth EA; Washington RA; Lucchesi BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):987-94. PubMed ID: 9618399
[TBL] [Abstract][Full Text] [Related]
4. Dermatan disulfate (Intimatan) prevents complement-mediated myocardial injury in the human-plasma-perfused rabbit heart.
Hong TT; White AJ; Lucchesi BR
Int Immunopharmacol; 2005 Feb; 5(2):381-91. PubMed ID: 15652767
[TBL] [Abstract][Full Text] [Related]
5. Effects of complement activation in the isolated heart. Role of the terminal complement components.
Homeister JW; Satoh P; Lucchesi BR
Circ Res; 1992 Aug; 71(2):303-19. PubMed ID: 1628389
[TBL] [Abstract][Full Text] [Related]
6. Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart.
Homeister JW; Satoh PS; Kilgore KS; Lucchesi BR
J Immunol; 1993 Feb; 150(3):1055-64. PubMed ID: 8423331
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the alternative complement pathway by sCR1[desLHR-A] protects the rabbit isolated heart from human complement-mediated damage.
Gralinski MR; Wiater BC; Assenmacher AN; Lucchesi BR
Immunopharmacology; 1996 Sep; 34(2-3):79-88. PubMed ID: 8886851
[TBL] [Abstract][Full Text] [Related]
8. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury.
Shandelya SM; Kuppusamy P; Herskowitz A; Weisfeldt ML; Zweier JL
Circulation; 1993 Dec; 88(6):2812-26. PubMed ID: 8252695
[TBL] [Abstract][Full Text] [Related]
9. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart.
Friedrichs GS; Kilgore KS; Manley PJ; Gralinski MR; Lucchesi BR
Circ Res; 1994 Oct; 75(4):701-10. PubMed ID: 7923616
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5.
Evans MJ; Rollins SA; Wolff DW; Rother RP; Norin AJ; Therrien DM; Grijalva GA; Mueller JP; Nye SH; Squinto SP
Mol Immunol; 1995 Nov; 32(16):1183-95. PubMed ID: 8559143
[TBL] [Abstract][Full Text] [Related]
11. Role of tissue factor-mediated coagulation in ischemia/ reperfusion-induced injury of Langendorf-perfused rabbit hearts.
Armaganian L; Kam G; Eisenberg PR; Schechtman KB; Abendschein DR
Coron Artery Dis; 2000 Sep; 11(6):481-7. PubMed ID: 10966134
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy.
Pross M; Lippert H; Misselwitz F; Nestler G; Krüger S; Langer H; Halangk W; Schulz HU
Thromb Res; 2003 Jun; 110(4):215-20. PubMed ID: 14512085
[TBL] [Abstract][Full Text] [Related]
13. CD59 prevents human complement-mediated injuries in isolated guinea pig hearts.
Wu S; Ma H; Huang S; Dong Y; Wu C; Shun J
Chin Med J (Engl); 2002 Feb; 115(2):175-8. PubMed ID: 11940325
[TBL] [Abstract][Full Text] [Related]
14. Heat stress protects the perfused rabbit heart from complement-mediated injury.
Gralinski MR; Black SC; Stancato LF; Kilgore KS; Campau PA; Park JL; Ozeck MJ; Pratt WB; Lucchesi BR
Am J Physiol; 1996 Aug; 271(2 Pt 2):H571-8. PubMed ID: 8770098
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion.
Kilgore KS; Tanhehco EJ; Naylor KB; Lucchesi BR
J Pharmacol Exp Ther; 1999 Sep; 290(3):1041-7. PubMed ID: 10454476
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.
Gralinski MR; Black SC; Kilgore KS; Chou AY; McCormack JG; Lucchesi BR
Cardiovasc Res; 1994 Aug; 28(8):1231-7. PubMed ID: 7954626
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of reviparin-sodium.
Hoppensteadt D; Jeske W; Fareed J
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S11-6. PubMed ID: 8180323
[TBL] [Abstract][Full Text] [Related]
18. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium.
Väkevä A; Morgan BP; Tikkanen I; Helin K; Laurila P; Meri S
Am J Pathol; 1994 Jun; 144(6):1357-68. PubMed ID: 7515561
[TBL] [Abstract][Full Text] [Related]
19. Prolonged support of working rabbit hearts using Fluosol-43 or erythrocyte media.
Segel LD; Ensunsa JL; Boyle WA
Am J Physiol; 1987 Feb; 252(2 Pt 2):H349-59. PubMed ID: 3812749
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.
Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Semin Thromb Hemost; 1995; 21(2):212-27. PubMed ID: 7660144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
